Using Fatty Acid-Binding Proteins as Potential Biomarkers to Discriminate between Parkinson’s Disease and Dementia with Lewy Bodies: Exploration of a Novel Technique
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241713267 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Ichiro Kawahata und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of CNS Drug Innovation, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan. Hauptthemen laut MEDLINE: Parkinson Disease, Synucleinopathies, Lewy Body Disease, Alzheimer Disease. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science, Japan AMED.
Themen: Demenz
Abstract (Originalsprache)
An increase in the global aging population is leading to an increase in age-related conditions such as dementia and movement disorders, including Alzheimer’s disease (AD), Parkinson’s disease (PD), and dementia with Lewy bodies (DLB). The accurate prediction of risk factors associated with these disorders is crucial for early diagnosis and prevention. Biomarkers play a significant role in diagnosing and monitoring diseases. In neurodegenerative disorders like α-synucleinopathies, specific biomarkers can indicate the presence and progression of disease. We previously demonstrated the pathogenic impact of fatty acid-binding proteins (FABPs) in α-synucleinopathies. Therefore, this study investigated FABPs as potential biomarkers for Lewy body diseases. Plasma FABP levels were measured in patients with AD, PD, DLB, and mild cognitive impairment (MCI) and healthy controls. Plasma FABP3 was increased in all groups, while the levels of FABP5 and FABP7 tended to decrease in the AD group. Additionally, FABP2 levels were elevated in PD. A correlation analysis showed that higher FABP3 levels were associated with decreased cognitive function. The plasma concentrations of Tau, GFAP, NF-L, and UCHL1 correlated with cognitive decline. A scoring method was applied to discriminate between diseases, demonstrating high accuracy in distinguishing MCI vs. CN, AD vs. DLB, PD vs. DLB, and AD vs. PD. The study suggests that FABPs could serve as potential biomarkers for Lewy body diseases and aid in early disease detection and differentiation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of CNS Drug Innovation, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan.
- Department of Neurology, National Hospital Organization Sendai Nishitaga Hospital, Sendai 982-0805, Japan.
ORCID-Profile: Ichiro Kawahata, Atsushi Takeda
Förderung
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
- Japan AMED
- Takeda Science Foundation
Zitieren
APA
Kawahata, I., Sekimori, T., Oizumi, H., Takeda, A., & Fukunaga, K. (2023). Using Fatty Acid-Binding Proteins as Potential Biomarkers to Discriminate between Parkinson’s Disease and Dementia with Lewy Bodies: Exploration of a Novel Technique. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241713267
Vancouver
Kawahata I, Sekimori T, Oizumi H, Takeda A, Fukunaga K. Using Fatty Acid-Binding Proteins as Potential Biomarkers to Discriminate between Parkinson’s Disease and Dementia with Lewy Bodies: Exploration of a Novel Technique. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241713267
BibTeX
@article{Kawahata2023,
author = {Kawahata, Ichiro and Sekimori, Tomoki and Oizumi, Hideki and Takeda, Atsushi and Fukunaga, Kohji},
title = {Using Fatty Acid-Binding Proteins as Potential Biomarkers to Discriminate between Parkinson’s Disease and Dementia with Lewy Bodies: Exploration of a Novel Technique},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241713267}
}
EUVIMED